狄诺塞麦主要用于治疗什么病症？

What conditions are it mainly used to treat? On May 28, 2010, the European Commission approved denosumab (desosumab) for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures in patients.

As research on denosumab continues to deepen, the diseases denosumab can treat are also expanding. On November 18, 2010, denosumab was approved to prevent bone-related events caused by cancer that has spread to the bone. On June 13, 2013, it was approved to treat adults and adolescents with giant cell tumor of bone (GCTB), a rare and usually noncancerous tumor.

Denosumab is a prescription drug and an injection. Patients must take the medication under the guidance of a professional doctor. Denosumab requires a subcutaneous injection of 120 mg into the upper arm, upper thigh, or abdomen every 4 weeks. Hypocalcemia must be corrected before starting treatment. Give calcium and vitamin D when needed to treat or prevent hypocalcemia.

The FDA approved denosumab (desosumab) for the treatment of bone metastases from solid tumors based on the results of three published pivotal clinical trials. Comprehensive analysis of these three studies showed that compared with zoledronic acid, denosumab prolonged the time to the patient's first adverse bone event (ARE) by 17%, or significantly delayed the median time to the first SRE by 8.2 months (27.6 months vs. 19.4 months). Denosumab also extended the time interval from the first time to the recurrence of SRE in the study by 18%, and the effect was very significant.

(Denosumab) is the first RANKL inhibitor approved by the FDA and is currently on the market in many countries or regions around the world. In 2019, denosumab entered the Chinese market, and more and more patients will benefit from denosumab treatment.